Taxonomy

Learn How CMTA is Accelerating Research and Empowering Patients

The Charcot-Marie-Tooth Association (CMTA) is transforming the future of CMT

Read More

CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery

CMTA announced today a $423,000 investment to address diagnostic gaps

Read More

Simply CMT Podcast Episode 2: Jonah Berger

Welcome to Episode 2 of the Simply CMT Podcast! Join

Read More

Encouraging News in CMT Research from CMTA-STAR Alliance Partner Alesta Therapeutics

Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies

Read More

CMTA’s New Video Aims to Increase Awareness About CMT

Charcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy,

Read More

Nervosave: Shaping the Future of Genetic Therapy for CMT1A

What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics,

Read More

CMTA-STAR Alliance Partner NMD Pharma Announces FDA Orphan Drug Designation for NMD670

NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that

Read More

CMTA 2024 Year in Review Magazine

In 2024, CMTA united the CMT community to achieve remarkable

Read More

Simply CMT Podcast

The Simply CMT Podcast is presented by the Charcot-Marie-Tooth Association.

Read More

CMTA-STAR Alliance Partner NMD Pharma Publishes Transformative Study on Charcot-Marie-Tooth Disease

CMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication

Read More